Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Psoralidin is a naturally occurring coumestan isolated from the seeds of *Psoralea corylifolia*. It exhibits significant anticancer, anti-inflammatory, and antioxidant properties. Its mechanism of action involves the inhibition of the NF-κB and PI3K/Akt signaling pathways, leading to the induction of apoptosis through increased Caspase-3 activity and the suppression of cell proliferation. Research has demonstrated its potential efficacy in various cancers, including esophageal, prostate, and lung cancers, as well as its role in modulating radiation-induced pulmonary inflammation and exhibiting antidepressant-like effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on psoralidin.